Sihuan Pharmaceutical Holdings Group Ltd
HKEX:460

Watchlist Manager
Sihuan Pharmaceutical Holdings Group Ltd Logo
Sihuan Pharmaceutical Holdings Group Ltd
HKEX:460
Watchlist
Price: 1.32 HKD Market Closed
Market Cap: 12.1B HKD

Sihuan Pharmaceutical Holdings Group Ltd
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Sihuan Pharmaceutical Holdings Group Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Sihuan Pharmaceutical Holdings Group Ltd
HKEX:460
Cash from Operating Activities
ÂĄ112.2m
CAGR 3-Years
-36%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash from Operating Activities
ÂĄ3.9B
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash from Operating Activities
ÂĄ501.5m
CAGR 3-Years
-56%
CAGR 5-Years
N/A
CAGR 10-Years
4%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash from Operating Activities
ÂĄ11.9B
CAGR 3-Years
60%
CAGR 5-Years
18%
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash from Operating Activities
ÂĄ4.7B
CAGR 3-Years
95%
CAGR 5-Years
-3%
CAGR 10-Years
8%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash from Operating Activities
ÂĄ4.1B
CAGR 3-Years
N/A
CAGR 5-Years
171%
CAGR 10-Years
N/A
No Stocks Found

Sihuan Pharmaceutical Holdings Group Ltd
Glance View

Market Cap
12.2B HKD
Industry
Pharmaceuticals

Sihuan Pharmaceutical Holdings Group Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 4,282 full-time employees. The company went IPO on 2010-10-28. The firm is mainly engaged in the research and development, manufacture and sales of pharmaceutical products in China. Its products are applicable in cardio-cerebral vascular (CCV) system, central nervous system, metabolism, oncology and anti-infective fields. Its CCV products include Kelinao, Anjieli and Oudimei, among others. Its non-CCV products include Ren’Ao, Metronidazole and Clindamycin, among others.

Intrinsic Value
0.5 HKD
Overvaluation 62%
Intrinsic Value
Price

See Also

What is Sihuan Pharmaceutical Holdings Group Ltd's Cash from Operating Activities?
Cash from Operating Activities
112.2m CNY

Based on the financial report for Jun 30, 2025, Sihuan Pharmaceutical Holdings Group Ltd's Cash from Operating Activities amounts to 112.2m CNY.

What is Sihuan Pharmaceutical Holdings Group Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-11%

Over the last year, the Cash from Operating Activities growth was -46%. The average annual Cash from Operating Activities growth rates for Sihuan Pharmaceutical Holdings Group Ltd have been -36% over the past three years , -11% over the past five years .

Back to Top